Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)

archived

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R33 applications; this mechanism is suitable for projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the R33 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-003, that solicits applications under the NIH Exploratory/Developmental R21 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $2,250,000 to this FOA in fiscal year 2010 to award up to 7 grants.

High